BX LAB TECHNICAL ARTICLE
APOC3 Oligonucleotides Advance on Two Regulatory Tracks
FDA and NMPA actions in 2026 show APOC3-targeted ASO and siRNA medicines advancing under distinct indications and regulatory histories.
Key takeaways
The June 2026 FDA action expanded TRYNGOLZA into severe hypertriglyceridemia; its original FCS approval dates to December 2024.
China's January 2026 approval of REDEMPLO covered FCS and should not be presented as an sHTG approval.
A shared APOC3 target does not make ASO-GalNAc and siRNA products interchangeable at the chemistry, evidence, or regulatory level.
Two developments should not be compressed into one approval story
An August 16 industry article from RNAinsights placed TRYNGOLZA and REDEMPLO within a broader account of small-nucleic-acid growth in cardiometabolic disease. The two developments are clearer when their separate regulatory histories are preserved. TRYNGOLZA was originally approved for FCS in December 2024; the June 2026 action was a supplemental sHTG approval. Arrowhead's January 2026 announcement states that the NMPA approved REDEMPLO for FCS.
TRYNGOLZA expanded from FCS into severe hypertriglyceridemia
The June 2026 TRYNGOLZA label covers adults with FCS and adults with severe hypertriglyceridemia. It describes olezarsen as an antisense oligonucleotide conjugated to GalNAc that binds apoC-III messenger RNA and promotes its degradation. The dosing framework differs by indication, reinforcing that the supplemental action added a distinct population and evidence package to an existing product history.
REDEMPLO entered China with an FCS indication
Arrowhead announced on January 7, 2026 that the NMPA had approved REDEMPLO, or plozasiran, for FCS. The company identified it as an siRNA medicine and said Sanofi would commercialize it in Greater China under rights acquired from Visirna Therapeutics. The approval triggered a $10 million milestone payment. The RNAinsights article also discusses the SHASTA-3 and SHASTA-4 development program in sHTG; that program is separate from the FCS indication covered by the Chinese approval.
A shared target does not make the modalities interchangeable
TRYNGOLZA is an ASO-GalNAc conjugate, while REDEMPLO is identified as an siRNA medicine. Sequence architecture, conjugation strategy, strand composition, impurity profile, analytical methods, and dose presentation are product-specific. A target-level narrative cannot substitute for a technical definition of the material or medicine under review.
Commercial indicators point to a broader RNA medicine market
Alnylam reported $1.03 billion in combined second-quarter 2026 TTR product revenue, including $1.012 billion for AMVUTTRA and $18 million for ONPATTRO. The RNAinsights article places these results alongside additional product sales and longer-term market projections. Because those figures come from different reporting periods and forecast methods, they are best read as directional industry context rather than as one directly comparable market total.
The practical reading is product-specific
Oligonucleotide medicines are reaching broader regulatory and commercial settings, but the evidence remains product-specific. Technical review should preserve the exact modality, sequence and conjugate architecture, indication, dose form, analytical definition, and regulatory version. Clinical and regulatory conclusions must also remain separate from specifications for research materials and intermediates.
References
Technical context is supported by the peer-reviewed literature below.